Literature DB >> 9769294

Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis.

T Takahashi1, M Munakata, I Suzuki, Y Kawakami.   

Abstract

Pulmonary alveolar proteinosis (PAP) is a disease characterized by the filling of alveolar spaces with periodic acid-Schiff-positive proteinaceous material and by the hypertrophy of type II pneumocytes in the alveolar interstitium. To examine if KL-6, a mucinlike glycoprotein, is useful for the diagnosis of PAP and the estimation of its activity, serum KL-6 levels in patients with PAP were measured by an enzyme-linked immunosorbent assay and compared with those of patients with other lung diseases. Furthermore, to estimate the origin of KL-6 in some patients, measurements of KL-6 levels in bronchoalveolar lavage (BAL) fluid and immunohistochemical staining of the lung tissues with a monoclonal antibody to KL-6 antigen were performed. Serum KL-6 levels in patients with PAP were extremely high and were significantly higher than those in patients with interstitial lung diseases in which elevation of serum KL-6 has been recognized. BAL-fluid KL-6 levels in patients with PAP were higher than serum levels. Both serum and BAL-fluid KL-6 levels in patients with PAP correlated well with the disease activity. Immunohistochemically, positive staining was observed in proliferating type II pneumocytes. These results suggest the usefulness of KL-6 measurement in the diagnosis and estimation of disease activity of PAP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9769294     DOI: 10.1164/ajrccm.158.4.9712003

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  15 in total

1.  Serum KL-6 levels in lung cancer patients with or without interstitial lung disease.

Authors:  Kunihiko Miyazaki; Koichi Kurishima; Katsunori Kagohashi; Mio Kawaguchi; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

2.  Tubulointerstitial nephritis with uveitis in Chinese adults.

Authors:  Cui Li; Tao Su; Rong Chu; Xiaomei Li; Li Yang
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-07       Impact factor: 8.237

3.  Atypical pulmonary alveolar proteinosis presenting as a mixed nodular ground-glass opacity with focal mucinosis mimicking lung cancer.

Authors:  Tsutomu Shinohara; Hiroyuki Hino; Shino Imanishi; Keishi Naruse; Yuji Ohtsuki; Fumitaka Ogushi
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  Serum KL-6 in pulmonary alveolar proteinosis: China compared historically with Germany and Japan.

Authors:  Wen-Liang Guo; Zi-Qing Zhou; Lu Chen; Zhu-Quan Su; Chang-Hao Zhong; Yu Chen; Shi-Yue Li
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

5.  Circulating KL-6 levels in patients with drug induced pneumonitis.

Authors:  H Ohnishi; A Yokoyama; Y Yasuhara; A Watanabe; T Naka; H Hamada; M Abe; K Nishimura; J Higaki; J Ikezoe; N Kohno
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

6.  Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan.

Authors:  Yoshikazu Inoue; Bruce C Trapnell; Ryushi Tazawa; Toru Arai; Toshinori Takada; Nobuyuki Hizawa; Yasunori Kasahara; Koichiro Tatsumi; Masaaki Hojo; Toshio Ichiwata; Naohiko Tanaka; Etsuro Yamaguchi; Ryosuke Eda; Kazunori Oishi; Yoshiko Tsuchihashi; Chinatsu Kaneko; Toshihiro Nukiwa; Mitsunori Sakatani; Jeffrey P Krischer; Koh Nakata
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

7.  Heterozygous ABCA3 mutation associated with non-fatal evolution of respiratory distress.

Authors:  Takuya Yokota; Yoshihiro Matsumura; Nobuhiro Ban; Tadashi Matsubayashi; Nobuya Inagaki
Journal:  Eur J Pediatr       Date:  2007-07-06       Impact factor: 3.183

8.  Carbon Nanotubes Exposure Risk Assessment: From Toxicology to Epidemiologic Studies (Overview of the Current Problem).

Authors:  L M Fatkhutdinova; T O Khaliullin; A A Shvedova
Journal:  Nanotechnol Russ       Date:  2015-05

Review 9.  Rare lung disease II: pulmonary alveolar proteinosis.

Authors:  Stephen C Juvet; David Hwang; Thomas K Waddell; Gregory P Downey
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

10.  Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis.

Authors:  Francesco Bonella; Shinichiro Ohshimo; Cai Miaotian; Matthias Griese; Josune Guzman; Ulrich Costabel
Journal:  Orphanet J Rare Dis       Date:  2013-04-04       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.